(S) -Zovegalisib
(S) -Zovegalisib ((S) -RLY-2608) is an S-enantiomer of of Zovegalisib (HY-153306) . Zovegalisib is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity[1].
Product Specifications
CAS Number
[2733573-93-6]
Product Name Alternative
(S) -RLY-2608
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Drug Isomer; PI3K
Related Pathways
Others; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Concentration
10mM
Purity
99.89
Solubility
DMSO : 40 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1N[C@H](C2=CC(F)=CC=C2Cl)C(C1=C3)=C(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)C=C3C5=C(C#N)N6C(C=C5)=NC=N6
Molecular Formula
C29H14ClF5N6O2
Molecular Weight
608.91
Precautions
H302, H315, H319, H335
References & Citations
[1]Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
032520-ML650 100 µL
BIN1, ID (BIN1, AMPHL, Myc box-dependent-interacting protein 1, Amphiphysin II, Amphiphysin-like protein, Box-dependent myc-interacting protein 1, Bridging integrator 1) (MaxLight 650) discontinued
Ask
View Details 
MBS7079555 Inquire
Recombinant Burkholderia pseudomallei Secretion apparatus protein BsaZ (bsaZ), partial
Ask
View Details 
